Senseonics - SENS Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SENS shares.
View SENS analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1-year target prices for Senseonics' shares. Their SENS share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 158.6% from the stock's current price.
View analysts price targets for SENS or view top-rated stocks among Wall Street analysts.

Senseonics' stock was trading at $2.88 at the beginning of the year. Since then, SENS shares have decreased by 59.7% and is now trading at $1.16.
View the best growth stocks for 2022 here.

Senseonics Holdings, Inc. (NYSEAMERICAN:SENS) posted its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.09. The company earned $4.62 million during the quarter, compared to analyst estimates of $4.06 million. Senseonics had a net margin of 2,317.41% and a negative trailing twelve-month return on equity of 132.13%.

Senseonics issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $15.00 million-$17.00 million, compared to the consensus revenue estimate of $16.41 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Senseonics investors own include VirnetX (VHC), Advanced Micro Devices (AMD), Micron Technology (MU), Nabriva Therapeutics (NBRV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Tandem Diabetes Care (TNDM), CytoDyn (CYDY), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."

Senseonics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.55%), Vanguard Group Inc. (4.70%), State Street Corp (2.36%), Renaissance Technologies LLC (0.39%), Nuveen Asset Management LLC (0.34%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Anthony R Raab, Douglas A Roeder, Douglas S Prince, Edward Fiorentino, Francine Kaufman, Mirasol Panlilio, Mukul Jain, Nick B Tressler, Stephen P Defalco and Timothy T Goodnow.
View institutional ownership trends.

Shares of SENS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SENS stock can currently be purchased for approximately $1.16.

Senseonics (NYSEAMERICAN:SENS) has a market capitalization of $554.78 million and generates $13.68 million in revenue each year. The company earns $-302,470,000.00 in net income (profit) each year or $0.21 on an earnings per share basis.

Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The official website for the company is www.senseonics.com. The company can be reached via phone at (301) 515-7260, via email at investors@senseonics.com, or via fax at 301-515-0988.